AFT Pharmaceuticals Ltd Ordinary Shares - Announcements

Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

AFT	AFT to announce full year results on May 23 2024		89.21KB	Share
AFT	AFT Licenses Maxigesic(R) IV in Brazil		113.62KB	Share
AFT	AFT,Massey Ventures,Gilles McIndoe to develop scar treatmen		117.85KB	Share
AFT	AFT makes further progress in international markets		122.8KB	Share
AFT	AFT updates operating profit guidance to $23m to $25m	PRICE SENSITIVE	144.72KB	Share
AFT	Maxigesic IV launched in the United States	PRICE SENSITIVE	346.8KB	Share
AFT	AFT further broadens R&D pipeline with new product		115.99KB	Share
AFT	NEW YEAR LETTER TO INVESTORS		172.04KB	Share
AFT	AFT broadens R&D pipeline with new product candidate		114.16KB	Share
AFT	AFT Pharma reports growth and global expansion	PRICE SENSITIVE	183.91KB	Share
AFT	AFT's Crystaderm(R) antiseptic approved for sale in China		109.88KB	Share
AFT	AFT welcomes US FDA approval for sale of Maxigesic IV	PRICE SENSITIVE	119.23KB	Share
AFT	AFT to announce half year interim results on Thurs Nov 23		88.73KB	Share
AFT	Retirement of Jon Lamb		106.26KB	Share
AFT	AFT appoints Andrew Lane as independent director		109.96KB	Share
AFT	Shareholder interests		406.75KB	Share
AFT	AFT Orphan Pharmaceuticals judgment		142.93KB	Share
AFT	Results of 2023 Annual Shareholder Meeting		143.6KB	Share
AFT	Jon Lamb intention to retire		106.27KB	Share
AFT	ASM chair address and presentation		158.12KB	Share
AFT	AFT signs new licensing agreement for ZENEO(R) Midazolam		258.22KB	Share
AFT	AFT extends e-commerce presence into Amazon US		124.04KB	Share
AFT	Notice of Annual Meeting of Shareholders 2023		417.29KB	Share
AFT	Annual Meeting and Closing Date for Director Nominations		119.52KB	Share
AFT	NOTICE PURSUANT TO LISTING RULE 7.12.1		162.45KB	Share
AFT	Distribution Notice		120.5KB	Share
AFT	AFT declares maiden dividend; record revenue	PRICE SENSITIVE	1.67MB	Share
AFT	AFT Pharmaceuticals to announce full year results on Monday		107.66KB	Share
AFT	US FDA sets PDUFA date for Maxigesic IV		143.12KB	Share
AFT	AFT submits Maxigesic IV(R) packaging data to the US FDA		123.37KB	Share
AFT	AFT Crystawash reg'n in China and new licencing agreements		103.68KB	Share
AFT	Maxigesic Rapid tablets gain US FDA approval	PRICE SENSITIVE	102.55KB	Share
AFT	AFT to develop antibiotic eye drop		117.2KB	Share
AFT	AFT announces Maxigesic IV(R) distribution agreement for nine		153.82KB	Share
AFT	2023 New Year letter to investors		182.52KB	Share
AFT	221124 Interim results FY23H1 App 2 amended	PRICE SENSITIVE	184.12KB	Share
AFT	AFT extends growth investment as sales surge	PRICE SENSITIVE	154.45KB	Share
AFT	AFT to announce half year interim results on Nov 24		88.58KB	Share
AFT	AFT update on Maxigesic IV(R) US registration filing		111.45KB	Share
AFT	AFT collaborates to develop birthmark medicine		119.91KB	Share
AFT	Results of 2022 Annual Shareholder Meeting		144.49KB	Share
AFT	AFT 2022 ASM chairman's address and presentation		161.82KB	Share
AFT	AFT Completes Pascomer Clinical Study and Takes Back Rights		294.81KB	Share
AFT	Dr Doug Wilson to step down from AFT Board		112.99KB	Share
AFT	AFT and RooLife launch OTC medicines online in China		124.81KB	Share
AFT	Notice of Annual Meeting of Shareholders 2022		433.07KB	Share
AFT	US FDA seeks more information on Maxigesic IV(R) application	PRICE SENSITIVE	137KB	Share
AFT	Disclosure of Directors and Senior Managers Relevant Intere		434.8KB	Share
AFT	Capital Change Notice - Issue of ordinary shares		123.17KB	Share
AFT	Annual Meeting and Closing Date for Director Nominations		119.59KB	Share
AFT	Capital Change Notice - Issue of ordinary shares		123.27KB	Share
AFT	Annual Report revision	PRICE SENSITIVE	7.6MB	Share
AFT	AFT full year results FY2022	PRICE SENSITIVE	187.22KB	Share
AFT	Capital Change Notice - Issue of ordinary shares		123.26KB	Share
AFT	Disclosure of Directors and Senior Managers Relevant Intere		434.04KB	Share
AFT	Capital Change Notice - Issue of ordinary shares		123.19KB	Share
AFT	AFT to announce full year results on Monday May 23 2022		87.35KB	Share
AFT	Capital Change Notice - Issue of ordinary shares		122.81KB	Share
AFT	AFT prevails in comparative advertising judgement		121.01KB	Share
AFT	AFT notes FDA approval for Pascomer alternative		116.08KB	Share
AFT	ASX farmaforce release on contract sales force partnership		293.61KB	Share
AFT	Disclosure of Directors and Senior Managers Relevant Intere		436.96KB	Share
AFT	2022 New Year letter to investors		330.37KB	Share
AFT	Disclosure of Directors and Senior Managers Relevant Intere		291.76KB	Share
AFT	AFT welcomes Australian Federal Court appeal success		115.53KB	Share
AFT	Amended Capital Change Notice - Issue of ordinary shares		124.19KB	Share
AFT	Capital Change Notice - Issue of ordinary shares		124.18KB	Share
AFT	re-issued FY22H1 Presentation		2.5MB	Share
AFT	AFT reaffirms guidance and progresses growth plan	PRICE SENSITIVE	225.45KB	Share
AFT	FDA confirms earlier than expected PDUFA date for Maxigesic		143.88KB	Share
AFT	AFT appoints McPherson's as Singapore distributor		124.12KB	Share
AFT	US FDA accepts Maxigesic IV(R) New Drug Application	PRICE SENSITIVE	166.57KB	Share
AFT	Maxigesic IV(R) registered in the UK and Ireland		153.1KB	Share
AFT	interim results announcement on Thursday November 18 2021		98.69KB	Share
AFT	AFT further extends Maxigesic(R) footprint; strengthens EU		160.85KB	Share
AFT	SECISSUE: AFT: Capital Change Notice - Issue of ordinary shares		123.08KB	Share
AFT	MEETING: AFT: Results of ASM 2021		144.78KB	Share
AFT	MEETING: AFT: ASM Presentation and Chair's address	PRICE SENSITIVE	160.62KB	Share
AFT	GENERAL: AFT: New clinical study - Novaliq NovaTears(R)+Omega-3 eye drops		177.77KB	Share
AFT	SHINTR: AFT: D&O Ongoing Disclosure - Louise Clayton		262.89KB	Share
AFT	SECISSUE: AFT: Capital Change Notice - Issue of ordinary shares		136.26KB	Share
AFT	GENERAL: AFT: Maxigesic(R) Oral Liquid gets first regulatory approval		131.04KB	Share
AFT	GENERAL: AFT: ASM 2021 Proxy form		88.83KB	Share
AFT	GENERAL: AFT: Maxigesic(R) IV launches in Germany and Austria		129.88KB	Share
AFT	MEETING: AFT: Notice of Annual Meeting of Shareholders 2021		161.77KB	Share
AFT	SECISSUE: AFT: Capital Change Notice - Issue of ordinary shares		136.19KB	Share
AFT	GENERAL: AFT: Annual Report		5.61MB	Share
AFT	MEETING: AFT: Annual Meeting and Closing Date for Director Nominations		129.41KB	Share
AFT	FLLYR: AFT: AFT delivers growth amid global disruptions	PRICE SENSITIVE	195.92KB	Share
AFT	GENERAL: AFT: AFT extends Maxigesic(R) IV license in South America		158.02KB	Share
AFT	GENERAL: AFT: AFT results announcement May 24 2021		69.21KB	Share
AFT	SECISSUE: AFT: Capital Change Notice - Issue of ordinary shares		114.39KB	Share
AFT	GENERAL: AFT: AFT licenses Maxigesic(R) IV in the US	PRICE SENSITIVE	148.85KB	Share
AFT	SHINTR: AFT: D&O Ongoing Disclosure - Louise Clayton		436.55KB	Share
AFT	SHINTR: AFT: D&O Ongoing Disclosure - Malcolm Tubb		430.39KB	Share
AFT	SECISSUE: AFT: Capital Change Notice - Issue of ordinary shares		135.97KB	Share
AFT	GENERAL: AFT: Crystawash(R) Extend distribution in UAE, Kuwait, Oman and Ke		183.67KB	Share
AFT	GENERAL: AFT: AFT secures new partners in Poland and Greece		124.97KB	Share
AFT	GENERAL: AFT: AFT updates earnings guidance	PRICE SENSITIVE	126.03KB	Share
AFT	GENERAL: AFT: AFT licenses Pascomer(R) for Europe		125.47KB	Share

AFT AFT to announce full year results on May 23 2024
03/05/24		89.21KB	Share
AFT AFT Licenses Maxigesic(R) IV in Brazil
01/05/24		113.62KB	Share
AFT AFT,Massey Ventures,Gilles McIndoe to develop scar treatmen
24/04/24		117.85KB	Share
AFT AFT makes further progress in international markets
04/03/24		122.8KB	Share
AFT AFT updates operating profit guidance to $23m to $25m
16/02/24	PRICE SENSITIVE	144.72KB	Share
AFT Maxigesic IV launched in the United States
07/02/24	PRICE SENSITIVE	346.8KB	Share
AFT AFT further broadens R&D pipeline with new product
19/01/24		115.99KB	Share
AFT NEW YEAR LETTER TO INVESTORS
09/01/24		172.04KB	Share
AFT AFT broadens R&D pipeline with new product candidate
22/12/23		114.16KB	Share
AFT AFT Pharma reports growth and global expansion
23/11/23	PRICE SENSITIVE	183.91KB	Share
AFT AFT's Crystaderm(R) antiseptic approved for sale in China
21/11/23		109.88KB	Share
AFT AFT welcomes US FDA approval for sale of Maxigesic IV
18/10/23	PRICE SENSITIVE	119.23KB	Share
AFT AFT to announce half year interim results on Thurs Nov 23
09/10/23		88.73KB	Share
AFT Retirement of Jon Lamb
28/09/23		106.26KB	Share
AFT AFT appoints Andrew Lane as independent director
28/09/23		109.96KB	Share
AFT Shareholder interests
18/09/23		406.75KB	Share
AFT AFT Orphan Pharmaceuticals judgment
29/08/23		142.93KB	Share
AFT Results of 2023 Annual Shareholder Meeting
04/08/23		143.6KB	Share
AFT Jon Lamb intention to retire
04/08/23		106.27KB	Share
AFT ASM chair address and presentation
04/08/23		158.12KB	Share
AFT AFT signs new licensing agreement for ZENEO(R) Midazolam
21/07/23		258.22KB	Share
AFT AFT extends e-commerce presence into Amazon US
11/07/23		124.04KB	Share
AFT Notice of Annual Meeting of Shareholders 2023
30/06/23		417.29KB	Share
AFT Annual Meeting and Closing Date for Director Nominations
26/05/23		119.52KB	Share
AFT NOTICE PURSUANT TO LISTING RULE 7.12.1
22/05/23		162.45KB	Share
AFT Distribution Notice
22/05/23		120.5KB	Share
AFT AFT declares maiden dividend; record revenue
22/05/23	PRICE SENSITIVE	1.67MB	Share
AFT AFT Pharmaceuticals to announce full year results on Monday
04/05/23		107.66KB	Share
AFT US FDA sets PDUFA date for Maxigesic IV
01/05/23		143.12KB	Share
AFT AFT submits Maxigesic IV(R) packaging data to the US FDA
18/04/23		123.37KB	Share
AFT AFT Crystawash reg'n in China and new licencing agreements
27/03/23		103.68KB	Share
AFT Maxigesic Rapid tablets gain US FDA approval
02/03/23	PRICE SENSITIVE	102.55KB	Share
AFT AFT to develop antibiotic eye drop
02/02/23		117.2KB	Share
AFT AFT announces Maxigesic IV(R) distribution agreement for nine
24/01/23		153.82KB	Share
AFT 2023 New Year letter to investors
09/01/23		182.52KB	Share
AFT 221124 Interim results FY23H1 App 2 amended
24/11/22	PRICE SENSITIVE	184.12KB	Share
AFT AFT extends growth investment as sales surge
24/11/22	PRICE SENSITIVE	154.45KB	Share
AFT AFT to announce half year interim results on Nov 24
10/10/22		88.58KB	Share
AFT AFT update on Maxigesic IV(R) US registration filing
02/09/22		111.45KB	Share
AFT AFT collaborates to develop birthmark medicine
01/09/22		119.91KB	Share
AFT Results of 2022 Annual Shareholder Meeting
05/08/22		144.49KB	Share
AFT AFT 2022 ASM chairman's address and presentation
05/08/22		161.82KB	Share
AFT AFT Completes Pascomer Clinical Study and Takes Back Rights
27/07/22		294.81KB	Share
AFT Dr Doug Wilson to step down from AFT Board
22/07/22		112.99KB	Share
AFT AFT and RooLife launch OTC medicines online in China
07/07/22		124.81KB	Share
AFT Notice of Annual Meeting of Shareholders 2022
05/07/22		433.07KB	Share
AFT US FDA seeks more information on Maxigesic IV(R) application
01/07/22	PRICE SENSITIVE	137KB	Share
AFT Disclosure of Directors and Senior Managers Relevant Intere
20/06/22		434.8KB	Share
AFT Capital Change Notice - Issue of ordinary shares
20/06/22		123.17KB	Share
AFT Annual Meeting and Closing Date for Director Nominations
30/05/22		119.59KB	Share
AFT Capital Change Notice - Issue of ordinary shares
26/05/22		123.27KB	Share
AFT Annual Report revision
23/05/22	PRICE SENSITIVE	7.6MB	Share
AFT AFT full year results FY2022
23/05/22	PRICE SENSITIVE	187.22KB	Share
AFT Capital Change Notice - Issue of ordinary shares
11/05/22		123.26KB	Share
AFT Disclosure of Directors and Senior Managers Relevant Intere
05/05/22		434.04KB	Share
AFT Capital Change Notice - Issue of ordinary shares
05/05/22		123.19KB	Share
AFT AFT to announce full year results on Monday May 23 2022
04/05/22		87.35KB	Share
AFT Capital Change Notice - Issue of ordinary shares
28/04/22		122.81KB	Share
AFT AFT prevails in comparative advertising judgement
08/04/22		121.01KB	Share
AFT AFT notes FDA approval for Pascomer alternative
05/04/22		116.08KB	Share
AFT ASX farmaforce release on contract sales force partnership
23/02/22		293.61KB	Share
AFT Disclosure of Directors and Senior Managers Relevant Intere
13/01/22		436.96KB	Share
AFT 2022 New Year letter to investors
07/01/22		330.37KB	Share
AFT Disclosure of Directors and Senior Managers Relevant Intere
22/12/21		291.76KB	Share
AFT AFT welcomes Australian Federal Court appeal success
09/12/21		115.53KB	Share
AFT Amended Capital Change Notice - Issue of ordinary shares
07/12/21		124.19KB	Share
AFT Capital Change Notice - Issue of ordinary shares
07/12/21		124.18KB	Share
AFT re-issued FY22H1 Presentation
18/11/21		2.5MB	Share
AFT AFT reaffirms guidance and progresses growth plan
18/11/21	PRICE SENSITIVE	225.45KB	Share
AFT FDA confirms earlier than expected PDUFA date for Maxigesic
15/11/21		143.88KB	Share
AFT AFT appoints McPherson's as Singapore distributor
05/11/21		124.12KB	Share
AFT US FDA accepts Maxigesic IV(R) New Drug Application
01/11/21	PRICE SENSITIVE	166.57KB	Share
AFT Maxigesic IV(R) registered in the UK and Ireland
19/10/21		153.1KB	Share
AFT interim results announcement on Thursday November 18 2021
12/10/21		98.69KB	Share
AFT AFT further extends Maxigesic(R) footprint; strengthens EU
21/09/21		160.85KB	Share
AFT SECISSUE: AFT: Capital Change Notice - Issue of ordinary shares
06/09/21		123.08KB	Share
AFT MEETING: AFT: Results of ASM 2021
06/08/21		144.78KB	Share
AFT MEETING: AFT: ASM Presentation and Chair's address
06/08/21	PRICE SENSITIVE	160.62KB	Share
AFT GENERAL: AFT: New clinical study - Novaliq NovaTears(R)+Omega-3 eye drops
29/07/21		177.77KB	Share
AFT SHINTR: AFT: D&O Ongoing Disclosure - Louise Clayton
15/07/21		262.89KB	Share
AFT SECISSUE: AFT: Capital Change Notice - Issue of ordinary shares
15/07/21		136.26KB	Share
AFT GENERAL: AFT: Maxigesic(R) Oral Liquid gets first regulatory approval
14/07/21		131.04KB	Share
AFT GENERAL: AFT: ASM 2021 Proxy form
08/07/21		88.83KB	Share
AFT GENERAL: AFT: Maxigesic(R) IV launches in Germany and Austria
08/07/21		129.88KB	Share
AFT MEETING: AFT: Notice of Annual Meeting of Shareholders 2021
06/07/21		161.77KB	Share
AFT SECISSUE: AFT: Capital Change Notice - Issue of ordinary shares
21/06/21		136.19KB	Share
AFT GENERAL: AFT: Annual Report
27/05/21		5.61MB	Share
AFT MEETING: AFT: Annual Meeting and Closing Date for Director Nominations
27/05/21		129.41KB	Share
AFT FLLYR: AFT: AFT delivers growth amid global disruptions
24/05/21	PRICE SENSITIVE	195.92KB	Share
AFT GENERAL: AFT: AFT extends Maxigesic(R) IV license in South America
05/05/21		158.02KB	Share
AFT GENERAL: AFT: AFT results announcement May 24 2021
04/05/21		69.21KB	Share
AFT SECISSUE: AFT: Capital Change Notice - Issue of ordinary shares
03/05/21		114.39KB	Share
AFT GENERAL: AFT: AFT licenses Maxigesic(R) IV in the US
28/04/21	PRICE SENSITIVE	148.85KB	Share
AFT SHINTR: AFT: D&O Ongoing Disclosure - Louise Clayton
14/04/21		436.55KB	Share
AFT SHINTR: AFT: D&O Ongoing Disclosure - Malcolm Tubb
14/04/21		430.39KB	Share
AFT SECISSUE: AFT: Capital Change Notice - Issue of ordinary shares
14/04/21		135.97KB	Share
AFT GENERAL: AFT: Crystawash(R) Extend distribution in UAE, Kuwait, Oman and Ke
12/04/21		183.67KB	Share
AFT GENERAL: AFT: AFT secures new partners in Poland and Greece
07/04/21		124.97KB	Share
AFT GENERAL: AFT: AFT updates earnings guidance
01/04/21	PRICE SENSITIVE	126.03KB	Share
AFT GENERAL: AFT: AFT licenses Pascomer(R) for Europe
17/03/21		125.47KB	Share

REFRESH

1 2

(20min delay)
Last $2.80		Change -0.100(3.45%)		Mkt cap ! n/a

Open	High	Low	Value	Volume
$2.88	$2.88	$2.80	$30.10K	10.67K

Buyers (Bids)

No.	Vol.	Price($)
0	4	$2.79

Sellers (Offers)

Price($)	Vol.	No.
$2.80	8726	0

Last trade - 13.00pm 10/05/2024 (20 minute delay)

AFT (NZSX) Chart

AFT Pharmaceuticals Ltd Ordinary Shares - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available